There have been 3 insider transactions in the 90-day period prior to the date of this filing from the activities of 3 individual insiders all of which have been purchases and resulted in the acquisition of 760,248 company shares. Relative to the preceding 90-day window of time, there are no insider transactions for the company.
This level of insider transactions is below that of the peer group average in the 324-company Bio Therapeutic Drugs peer group over the last 90-day period. Activity in the peer group averaged 45.0 transactions per company, with company insiders acquiring on average 18,809 shares.
SEC Story Link http://www.sec.gov/Archives/edgar/data/1698530/000169853020000021/xslF345X03/wf-form4_158436280737371.xml
|Analyst Actions: Telsey Advisory Lifts Burlington St...|
|Tecogen to Delist From Nasdaq, Move to OTC Markets; ...|
|Analyst Actions: Morgan Stanley Lifts Burlington Sto...|
|Analyst Actions: BTIG Research Initiates Coverage on...|
|Tetraphase Pharmaceuticals Gets Revised Offer From A...|